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1. Introduction 
Lesioning of the nervous system can produce a form of pathological pain called 
“neuropathic pain” that is characterized by sensory deficit, burning sensation, hyperalgesia 
and allodynia (Cui et al., 2000). The mechanisms underlying neuropathic pain have been 
studied extensively. Abundant evidence has indicated that aside from the neural 
component, the non-neural cells of the CNS, such as glial cells, have important roles in the 
pathogenesis of pain (Coyle, 1998). To a certain extent, glial activation is triggered secondary 
to injury. Glial cells play an important role in the initiation, development and maintenance 
of persistent neuropathic pain. Both microglia and astrocytes are activated in the spinal cord 
after nerve injury, and pain is amplified when glia become activated (Mika, 2008). It has 
been hypothesized that neuropathic pain and morphine tolerance share some common 
pathological mechanisms (Mayer et al., 1999). Many studies have indicated that neuropathic 
pain leads to reduced morphine efficacy and the rapid development of morphine tolerance. 
The glia become activated in response to the repeated administration of morphine, which 
leads to the release of proinflammatory mediators and may oppose opioid analgesia by 
altering neuronal excitability (Campbell et al., 2006). It is not clear how opioids activate 
microglia in the spinal cord, but previous work by Hutchinson’s team suggested the 
possible involvement of toll-like receptor 4 (TLR4) (Tanga et al., 2005). In this study, we tried 
to understand the role of microglia in morphine tolerance and also examine some possible 
methods for improving the efficacy of morphine to control neuropathic pain. 
2. Basic mechanisms of neuropathic pain 
Pain is a sensory system that, under normal conditions, is protective and adaptive. It serves 
as a warning signal for the body (tissue inflammation and damage) and induces behavioral 
changes that facilitate wound healing and recuperation and help to prevent further tissue 
damage (Bridges et al., 2001). Lesioning of the nervous system can produce a form of 
pathological pain called “neuropathic pain”. Neuropathic pain is a debilitating condition 
that affects millions of individuals worldwide (Colburn et al., 1999; Zimmermann, 2001). It 
is characterized by sensory deficit, burning sensation, hyperalgesia and allodynia (Coyle, 
1998). Changes in signal processing in the nervous system may contribute to or may become 
the sole cause for hyperalgesia and allodynia (DeLeo & Yezierski, 2001). A lesion in the 
peripheral nervous system may induce pain, but simply severing dorsal roots seems to have 
little chance of causing lasting pain (Li et al., 2000).  
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Combining inflammatory substances with nerve injury enhances pain behavior (Clatworthy et 
al., 1995), and there is a strong correlation between the presence of mechanical allodynia in 
different nerve injury models (Cui et al., 2000; Mirzaei et al., 2010). A neuroma forms when the 
nerve is injured. The spontaneous activity and ectopic sensitivity to mechanical, thermal, and 
chemical stimuli that originate from the traumatic neuroma have been well documented 
(Devor, 2006). It has been demonstrated that there is a large increase in the level of 
spontaneous firing in the afferent neurons linked to the injury site. Abnormal pain after 
peripheral nerve injury is dependent on the activation of spontaneous and persistent abnormal 
discharge from ectopic foci at the site of injury (Wall & Gutnik, 1974) and the dorsal root 
ganglia (DRG) (C. N. Liu et al., 2000). This spontaneous discharge has been termed ectopic 
discharge and has also been demonstrated in humans suffering from neuropathic pain 
(Nordin et al., 1984). Pain is exacerbated in part because of a reorganization of spinal cord 
circuitry in the setting of persistent injury (Basbaum, 1999). This leads to the prolonged 
hyperexcitability of spinal cord neurons, which alters transmission of the pain message. 
Enhanced sensitivity to pain may persist long (months and years) after the primary tissue 
damage has healed (Dworkin et al., 2003; DeLeo & Yezierski, 2001). Chemical and neural 
changes occur, at the site of tissue injury, at the nerve endings of pain fibers, along their axons, 
at first –order synapses, and both pre-and post synaptically in the dorsal horn of the spinal 
cord or in supra-spinal pain-processing areas. This processing, from the normal condition to a 
pain – facilitatory state, in the dorsal horn of the spinal cord is collectively known as central 
sensitization (G. Woolf & Salter, 2000). Pain can transform from a symptom to a disease when 
injury or inflammation is prolonged (Hucho & Levine, 2007; C. J. Woolf & Mannion, 1999). The 
alteration of central sensory processing by sensitization of the spinal cord seems to be the key 
step for many sensory abnormalities in the context of neuropathic pain (Gracely et al., 1993; 
Roberts, 1986). There has been a great deal of research into the mechanisms of chronic pain, 
with a strong focus on the development of central sensitization. Changes in dorsal horn 
neuronal excitability can be achieved by increasing the excitatory input or by decreasing the 
inhibitory tone. This concept of disinhibition has been of considerable interest as a key 
mediator of the transmission of augmented sensory input to higher CNS regions in 
neuropathic pain states. The majority of currently used neuropathic pain models display 
similar alterations in hind-limb cutaneous sensory thresholds following partial injury of a 
peripheral (usually sciatic) nerve. In particular, the demonstration of hyperalgesia to noxious 
thermal stimuli and allodynia to cold and mechanical stimuli are used as outcome measures 
(Bridges et al., 2001; Bennett, 2005). The three most commonly used models are the chronic 
constriction injury (CCI) of the sciatic nerve (Bennett & Xie, 1988), the partial sciatic nerve 
ligation model (PNL) (Seltzer et a1., 1990) and the spinal nerve ligation model (SNL) (Kim et 
al., 1999). We investigated the characteristics of a CCI neuropathic model from behavioral, 
molecular and electrophysiological perspectives. In our laboratory, the CCI model produced 
robust behavioral changes in terms of pain sensation. Findings reveal that the CCI procedure 
produces long-lasting cold and mechano-allodynia as well as hypersensitivity to noxious 
stimulation (Hamidi et al., 2006). Microscopic studies of the injured nerves have revealed 
pathological changes distal to the injured site (see Fig. 1). There is massive degeneration of 
myelinated axons and less marked damage to unmyelinated axons (Basbaum et al., 1991; 
Manaheji et al., 2005). It is believed that allodynia is a central phenomenon mediated by large 
myelinated fibers (Yamamoto & Yaksh, 1992). In the injured nerve, the evoked compound 
action potentials (CAPs) including conduction velocity (CV), amplitude and rising time have 
become standard tools for the evaluation of peripheral nerve disorders and the investigation of 
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the function of the sciatic nerve. Recent research has shown that reduced CV can be caused by 
demyelination in the zone of the lesion (Basbaum et al., 1991). In our study, we found that the 
injury leads to a decrease in the CV and amplitude as well as an increase in the rising time of 
the CAPs (see Fig. 2). These changes are more pronounced in the recordings obtained distally 
to the ligated site. It seems that the sciatic nerve injuries yield changes in behavioral responses 
that are in accordance with the electrophysiological events that occur only in the distal part of 
the ligation site (Hamidi et al., 2006). Peripheral nerve injury is associated with inflammatory 
responses at the site of tissue damage. CNS injury is accompanied by the release of 
proinflammatory cytokines (Verri et al., 2006). Proinflammatory cytokines, especially tumor 
necrosis factor-ǂ (TNF- ǂ), interleukin (IL)-1 and IL-6, induce long-term alteration of synaptic 
transmission in the CNS and play a critical role in the development and maintenance of 
neuropathic pain (DeLeo & Yezierski, 2001). 
 
Fig. 1. Photomicrographs of toluidine blue stained semi-thin cross sections from normal 
sciatic (control or A). CCI 2 or B = two weeks after CCI. CCI 8 or C = eight weeks after CCI. 
Small myelinated fibers (arrows) are shown in A&C, ruffled basal lamina (double head 
arrow) in B, Schwann cells or phagocytic cells containing myelin debris (thin arrows) in B, 
damaged axons (thick arrows)in B. Atrophic axons (double arrow heads ) and Schwann cells 
(arrow head )and blood vessel(V) in B. 
 
Fig. 2. Histograms of conduction velocity (CV) of the compound action potential (CAP) 
recorded from the sciatic nerve proximally. Location of stimulation was proximal (CP) or 
distal (CD) to the level of the constriction. A: The CV decreased in both operated CCI rats 
compared to the sham animals. B: amplitude of CAPs decreased in both CD and CP groups 
when compared to the sham animals. C: comparison of the rising time of CAPs represents a 
significant increased between the CD and CP and the sham animals. Asterisks indicate 
significant differences between CP and CD with sham. Crosses indicate significant 
difference between CD and CP.  
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3. Opioid tolerance in neuropathic pain 
The perception of pain is modulated by pain-inhibitory and pain-facilitatory systems. The 
activation of several areas in the dorsal horn of the spinal cord results in the secretion of 
modulatory compounds that produce pain suppression (analgesia) or pain facilitation 
(hyperalgesia). Pain facilitation is mediated by many substances, including cholecystokinin 
(CCK), prostaglandins, dynorphin, substance P, and sympathetic amines (Mayer et al., 1999; 
Verri et al., 2006), and can be blocked by NMDA-receptor antagonists (Ben-Eliyahu et al., 
1992; Parsons, 2001). Researchers are working to characterize the changes that occur in the 
nervous system during the development of neuropathic pain in animal models. An 
understanding of how neuropathic pain develops is necessary to guide the development of 
new pain therapies. Unfortunately, neuropathic pain is generally resistant to currently 
available treatments, so treatment options for neuropathic patients are limited, as opioids 
and other available pharmacological treatments are not able to adequately control associated 
spontaneous pain (Colburn et al., 1999). Non-steroidal anti–inflammatory drugs, 
antidepressants and local anesthetic agents are generally ineffective or have substantial 
drawbacks due to side effects. Generally, these treatments do not protect neurons from 
stress or death. Recent evidence suggests that NMDA receptor antagonists may have a role 
in attenuating the features of neuropathic pain. Glutamate concentration increases in the 
ipsilateral dorsal horn after CCI (Kawamata & Omote, 1996). It has been established that 
hyperalgesia can be prevented in the CCI model by continual pre- and post-injury i.p. 
administration of the NMDA receptor antagonist MK-801 (Davar et al., 1991). The 
endogenous opioid system plays a pivotal role in pain suppression. The administration of 
exogenous opioid drugs can also activate this system (Shavit et al., 2007). Notably, opioid 
compounds (e.g., morphine) have been used for centuries to combat many extremely painful 
conditions. Opioids are among the most effective analgesics for many types of pain (Rashid 
et al., 2004). However, opioids are reported to have suboptimal therapeutic efficacy against 
neuropathic pain (Bleeker et al., 2001; Cherny et al., 1994). There have been reports that 
chronic morphine treatment leading to 'morphine tolerance' may indeed induce the death of 
neurons (Hameed et al., 2010; Mao et al., 2002). The ineffectiveness of morphine in the 
context of neuropathic pain may be due to the reduced number of presynaptic opioid 
receptors due to the degeneration of primary afferent neurons, which is in turn caused by 
nerve damage. In our study, we treated rats with morphine and MK-801 both separately and 
together prior to CCI injury. This anti-nociceptive treatment prevents the establishment of 
altered central processing, which amplifies post-CCI pain. Therefore the application of 
morphine or MK-801 exerts a minimal effect on allodynia and hyperalgesia phenomena. 
However, the co-administration of morphine and MK-801 effectively modulates some 
aspects of neuropathic pain related to behavioral disorders in allodynia induced by extreme 
cold (Hamidi et al., 2006; Nichols et al., 1997). It has been hypothesized that neuropathic 
pain shares cellular and molecular mechanisms of neural plasticity with opioid tolerance. 
Additional evidence for this hypothesis came from a study by (Ossipov et al. 1995), which 
observed the same result with experimental animal models of neuropathic pain. A reduction 
in the number of µ-opioid receptors may be an important factor in diminishing the efficacy 
of morphine and µ-opioid receptor agonists (Przewlocki & Przewlocka, 2001). Partial sciatic 
nerve injury caused a drastic decrease in µ-opioid receptor expression in the injured DRG 
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neurons (Rashid et al., 2004). Most previous studies examined the reasons behind the 
decreased effectiveness of spinal morphine in neuropathic pain, which includes reduced µ-
opioid receptor (mOR) expression in the spinal dorsal horn (Porreca et al., 1998). It is well 
known that mOR expression is greatly decreased in the dorsal root ganglion neurons after 
peripheral nerve injury (Zang et al., 1998). In contrast, the functional activity of the central 
and peripheral opioid systems is enhanced by inflammation (Bilevicute-Ljungar et al., 2006). 
It has been shown that during inflammation, the effect of µ-opioid receptor agonists 
increases by approximately 10-fold (Cook & Nickerson, 2005). In a study from our 
laboratory, the effect of persistent arthritis inflammation on spinal µ-opioid receptor 
expression and variation in hyperalgesia was examined. The results indicated a significant 
increase in spinal µ-opioid receptor mRNA expression, which was demonstrated by 
semiquantitative RT-PCR in the first week after arthritis induction. There were also 
significant ipsilateral changes in thermal hyperalgesia after arthritis. However, in a 21-day 
study, both µ-opioid receptor mRNA expression and thermal hyperalgesia gradually 
decreased and achieved levels that were close to normal. It seems that µ-opioid receptor 
fluctuation may be involved in changes in hyperalgesia during the 21 days after arthritis 
(see Fig. 3).  
 
Fig. 3. Comparison of variation in thermal hyperalgesia after naloxone injection on day 6 
and 21 days after induction of adjuvant arthritis (AA). (□), AA; (■), AA + naloxone. Data are 
the mean ±SEM (n= 6-7/ group). P < 0.001. ٭٭٭ P < 0.01, ٭٭ P < 0.05, ٭ 
Our results demonstrate that opioid receptor mRNA expression and variation in 
hyperalgesia are time dependent (Zaringhalam et al., 2008). Cytokines may play an 
important role in this mechanism by up-regulating mOR expression in the CNS. It is 
believed that excess IL-6 plays a pathogenic role in inflammation. In another set of 
experiments in our lab, we considered the role of IL-6 in arthritis. IL-6 is a multifunctional 
cytokine with pro- and anti-inflammatory properties. IL-6 mediates both acute and chronic 
phases of inflammatory responses and is therefore involved in both the early and late stages 
www.intechopen.com
 
Basic Principles of Peripheral Nerve Disorders 
 
152 
of inflammation (Moller & Villiger, 2006). Our study demonstrated that serum IL-6 and 
spinal mOR expression increased with concurrent decreases in hyperalgesia during the 
chronic phase of arthritis. This finding supports the hyperalgesic role of IL-6 during chronic 
inflammation. Our previous studies demonstrated that IL-6 administration resulted in 
analgesia, which was blocked by naloxone. This analgesia for sustained inflammatory pain 
was attributed to a local release of endogenous opioid peptide by immune cells after IL-6 
challenge (Tekieh et al., 2011). These results demonstrated an anti-inflammatory effect of 
serum IL-6 during the chronic phase of arthritis (see Fig. 4). It has been suggested that IL-6 
may serve as a regulator of inflammatory pain and may be essential in the immune-opioid 
pathway (De Jongh et al., 2003). Systemic administration of anti-IL-6 antibody reduced 
spinal mOR expression and subsequently increased hyperalgesia. IL-6 is an important 
cytokine for transitioning between acute and chronic inflammation and is involved in 
different stages of arthritis (Nishimoto & Kishimot, 2006). In another study we revealed an 
increase in the serum level of IL-6 in CCI animals which was blocked by minocyline and 
produced antinocicepion (Zanjani et al., 2006). These results suggest that the stages of 
inflammation in arthritis and the pain behaviors in CCI must be considered to achieve 
effective anti-hyperalgesic and anti-inflammatory intervention via anti-IL-6 antibody and 
analgesic effect of minocycline treatment respectively. 
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Fig. 4. CFA injection caused significant increased in spinal mOR expression time 
dependently. Anti- IL-6 antibody administration significantly reduced spinal mOR 
expression during different stages of AA. Ratio of spinal mOR protein band intensity in AA 
group significantly decreased at 14th and 21th days after anti-IL-6 antibody treatment 
compared to AA control group. Data are presented as mean ±SEM (n=6/ group). +++ P < 
0.001 comparison of ratio of spinal mOR protein band intensity between different days of 
AA. ٭٭ P < 0.01, ٭٭٭ P < 0.001 comparison of spinal mOR protein band intensity between 
AA and AA + anti-IL-6 antibody treated rats. ### P < 0.001 indicated spinal mOR protein 
band intensity difference in AA and AA + anti-IL-6 antibody treated rats between 14th and 
21th days. 
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4. Glial and opioid tolerance 
As with peripheral mechanisms, much evidence supports the view that the initiation but not 
the maintenance of neuropathic pain behaviors is associated with immune mechanisms (Xu 
et al., 2006). Central glial activation is a player in this complicated nociceptive signaling 
cascade. It has become evident that spinal cord glial cells play a major role in pain 
facilitation (Campbell & Meyer, 2006; Watkins & Maier, 2002). It is proposed that 
neuropathic pain leads to reduced morphine efficacy and to the development of morphine 
tolerance. The results of many studies support the idea that the modulation of glial and 
neuroimmune activation may be a potential therapeutic mechanism to enhance morphine-
induced analgesia (Mika, 2008). The analgesic potency of both systemic and intrathecal 
morphine is greatly reduced in animal models of neuropathic pain (Idanpaan et al., 1997). 
Recent evidence suggests that nerve damage evokes a cascade of immune responses and 
that glia play a crucial role in the maintenance of neuronal homeostasis in the central 
nervous system (Nakajima & Kohsaka, 2001; Stoll & Jander, 1999). In recognizing that glial 
cells play a role in chronic pain, one of the most important findings was that P2X receptors 
resided on glial cells, not on neurons (Sutherland, 2004). P2X receptors, or pain-signaling 
molecules, have long been associated with pain, but they were perceived to be associated 
with nerve cells. As a result of this discovery, researchers began inspecting the mechanisms 
of glial activation more closely (DeLeo, 2006). The mechanisms for this activation might be 
multifactorial. The glia become activated in response to the repeated administration of 
morphine, which leads to the release of proinflammatory mediators and may oppose opioid 
analgesia by altering the level of neuronal excitability. It has been increasingly recognized 
that spinal cord glial cells such as microglia and astrocytes play a critical role in the 
induction and maintenance of neuropathic pain by releasing powerful neuromodulators 
such as proinflammatory cytokines and chemokines. Recent evidence identifies chemokines 
as new players in pain control (Gao & Ji, 2010). Targeting glial activation is a clinically 
promising method for the treatment of neuropathic pain (Mika, 2008). Glial cells represent 
70% of the cells in the central nervous system (CNS), and microglia represent 5–10% of glial 
cells under normal conditions. Microglia cells have a small soma bearing thin and branched 
processes under normal conditions. They are the first non-neural cells to respond to a CNS 
perturbation such as nerve injury or chronic opioid administration (Raghavendra et al., 
2002; Tanga et al., 2004). They play a crucial role in the maintenance of neuronal 
homeostasis in the central nervous system. It seems that microglia might be responsible for 
the initiation of neuropathic pain states (Marchand et al., 2005), and their production of 
immune factors is believed to play an important role in nociceptive transmission (Colburn, 
1999; Watkins, et al., 2001). Nerve injury distal to the dorsal root ganglia leads to microglial 
activation. However, activation after dorsal rhizotomy is much reduced, in keeping with the 
observation that dorsal rhizotomy leads to less impressive hyperalgesia as compared to 
spinal nerve lesions involving the identical root (Willis et al., 2006). After activation, 
microglia cells change morphology from a resting, ramified shape into an active, amoeboid 
shape (Stoll & Jander, 1999). Activated microglia have dual regulatory functions in the 
maintenance and facilitation of tissue homeostasis in the CNS. They remove dead cells or 
dangerous debris by releasing toxic factors and phagocytosis, but they also repair injured 
cells by releasing neurotrophic factors (Quattrini et al., 1996). The exact mechanism of 
microglia cell activation may involve the release of algesic factors such as ATP, glutamate 
and nitric oxide from injured or hyperactive neurons (Inoue, 2006; Watkins & Maier, 2005). 
Microglial activation can alter the activity of opioid systems, and neuropathic pain is 
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characterized by resistance to morphine. The major proinflammatory cytokines (IL-1, IL-6 and 
TNF-ǂ) oppose acute opioid analgesia. Their effects may interact because suppressing the 
action of any single cytokine unmasks continuing analgesia (Hutchinson et al., 2008). The 
spinal cellular source of the proinflammatory signal was also of interest. Studies of normal 
spinal cord document the basal expression of proinflammatory cytokines in glia and to some 
extent in neurons, suggesting that under acute conditions, both glial and neural stores may be 
available to oppose opioid analgesia. The potentiation of acute morphine analgesia by 
minocycline suggests that microglia may prove to be a significant source of mediators that 
oppose opioid analgesia (Fu et al., 2006). Nevertheless, later reports that studied hyperalgesia 
in the spinal cord revealed that cytokines were indeed being secreted in a chronic pain state 
(Wieseler-Frank et al., 2005). These proinflammatory cytokines, specifically tumor necrosis 
factor (КB-TNF-ǂ), interleukin-1 (IL-1), and interleukin-6 (IL-6), are proteins that are vital in 
immune-to-brain communication (Sweitzer et al., 2002; Watkins & Maier, 2005; Watkins & 
Milligan, 2001). It has been found that propentofylline, pentoxifylline, fluorocitrate, ibudilast 
and minocycline decrease microglial and astroglial activation and inhibit proinflammatory 
cytokines, thereby suppressing the development of neuropathic pain (Mika, 2008; 
Raghavendra et al., 2004). Interathecal delivery of the antibiotic minocycline, an inhibitor of 
microglial activation, attenuates neuropathic pain (Raghavendra et al., 2003). Some glial 
inhibitors, which are safe and clinically well tolerated, are potentially useful agents for the 
treatment of neuropathic pain and for the prevention of tolerance to morphine analgesia. 
Evidence exists for a role of the ATP receptors P2X4 and/or P2X7, both of which are expressed 
on microglia. The chemokine fractalkine may also be involved, as blockade of its receptor, 
CX3CR1, attenuates hyperalgesia in neuropathic pain models (Milligan et al., 2005).  
Pentoxifylline is a non-specific cytokine inhibitor and an inhibitor of phosphodiesterase that 
can inhibit the synthesis of TNF-ǂ, IL-1ǃ and IL-6. Some studies have demonstrated that 
pentoxifylline influences the development of neuropathic pain behavior in rats and mice (J. 
Liu et al., 2007; Mika et al., 2007). The local injection of pentoxifylline reduced inflammatory 
pain by decreasing TNF-ǂ (Dorazil-Dudzik et al., 2004). When injected in a preemptive 
analgesia schema, it reduces postoperative pain in patients (Dobrogowski et al., 2005).The 
anti-nociceptive effects of pentoxifylline are correlated with a reduced production of TNF-ǂ, 
IL-1ǃ, and IL-6 through the inhibition of nuclear factor-КB as well as the stimulation of IL-10 
expression in the spinal cord and brain (Vale et al., 2004). However, the therapeutic effects of 
pentoxifylline on developed neuropathic pain remain to be determined by future studies. 
Minocycline, a semi-synthetic second-generation tetracycline with adequate penetration into 
the brain and cerebrospinal fluid (Colovic & Caccia, 2003), has emerged as a potent inhibitor of 
microglial activation and proliferation, without any known direct action on astrocytes or 
neurons (Tikka et al., 2001). The effects of minocycline are mediated by microglial cells and are 
distinct from the antimicrobial actions of this drug (He et al., 2001). The administration of 
minocycline either systemically or intrathecally attenuated hyperalgesia in rat models of 
neuropathy. The effect is associated with an inhibition of spinal microglial activation and the 
attenuated expression of proinflammatory cytokines (Ledeboer et al., 2005; Mika et al., 2007). It 
is emphasized that minocycline attenuated the development of behavioral hypersensitivity in 
the rat model of neuropathic pain when the inhibitor was injected preemptively (Raghavendra 
et al., 2003). However, the analgesic effects of minocycline in a rat model of neuropathic pain 
result from attenuated expression of IL-1ǃ, IL-6, TNF-ǂ, IL-1ǃ-converting enzyme, TNF-ǂ-
converting enzyme, an IL-1ǃ receptor antagonist and IL-10 in the lumbar dorsal spinal cord. 
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Activation of microglial cells occurs in the dorsal horn, and this activation may play a vital role 
in initiating central sensitization. The role of this activation in ongoing neuropathic pain is less 
clear. The sensation of pain begins with a simple thesis: nociceptors encode information about 
noxious stimuli and propagate these messages to the CNS; then, pain is felt. In the case of 
neuropathic pain, however, we see that a complex biology is at play (Campbell et al., 2006). 
Recent studies indicate that preemptive treatment with glial inhibitors seems to be more 
effective than their administration after glial cells have already been activated (Raghavendra et 
al., 2003). We observed similar results with minocycline. Preemptive treatment with 
minocycline in our study attenuated hyperalgesia and allodynia in CCI. We observed that 
minocycline, which was reported to have a neuroprotective effect in some neurodegenerative 
diseases, reversed hyperalgesia and allodynia due to sciatic nerve ligation and inhibited 
interleukin-6 production (see Fig. 5).  
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Fig. 5. Serum concentration of interleukin-6 in CCI saline-treated, sham-operated and CCI 
minocycline – treated rats on day 14 post- ligation. Data are presented as mean ±SEM of 6 
rats in each group. ٭٭٭ P < 0.001 indicate a statistically significant difference when 
compared to CCI saline - treated rats. M10 = minocycline 10 mg/kg, M20 = minocycline 20 
mg/kg, M40 = minocycline 40 mg/kg  
It seems that minocycline could have an anti-inflammatory and analgesic effect in some 
chronic pain states (Zanjani et al., 2006). As chronic morphine activates spinal cord glia, glial 
activation causes morphine tolerance, and both neuropathic pain and morphine tolerance 
share the same mechanism (Mayer et al., 1999), we sought to understand the role of microglia 
in the morphine tolerance observed following the administration of glial inhibitors 
(pentoxifylline and minocycline) after glial cells have already been activated. We administered 
Pentoxifylline and Minocyclines i.p. after chronic opioid treatment in a CCI model. 
Interestingly, the results demonstrated the attenuation of hyperalgesia and allodynia. This 
suggests a glial contribution in changing nociceptive processing, which could be blocked by 
glial inhibitor agents and enhance the analgesic effect of morphine. Some studies have 
suggested that glial-derived fractalkine is an endogenous regulator of morphine analgesia. It is 
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involved in increasing pain sensitivity, which occurs after chronic opioid treatment (Verge 
et al., 2004). Several other possible mechanisms involving activated glia have been 
suggested, such as morphine-induced p38 MAPK activation in microglia, changes in the glial 
regulation of glutamatergic NMDA receptors and the release of excitatory amino acids, 
prostaglandins and dynorphin (Svensson et al., 2006). Recent works have indicated that 
microglia are responsible for opioid tolerance and dependence (Guo & Schluesener, 2007). It 
is not clear how opioids activate microglia in the spinal cord, but previous work by 
Hutchinson's team suggested the possible involvement of toll-like receptor 4 (TLR4). The 
results indicate a role for the pattern recognition receptor TLR4 in microglial activation, 
which provides a link between central sensitization and innate immune responses. Levels of 
spinal mRNA for TLR4 are increased after L5 SNL (Tanga et al, 2005). TLR4 is involved in 
neuropathic pain and the dysregulation of opioid actions (Hutchinson et al, 2008). Notably, 
morphine upregulates TLR4 expression in microglia (Hutchinson et al., 2007). The 
neuropathic pain arising from CCI is created in part via activation of TLR4, which 
contributes to microglial activation. These data suggest that TLR4 may prove to be a target 
worth exploring to improve clinical pain control (Hutchinson et al., 2008). 
5. Conclusion 
These findings suggest that the analgesic efficacy of opioid is reduced by glial activation, 
and the release of proinflammatory cytokines may have implications for the treatment of 
pain. Blocking agents may improve the effectiveness of morphine. Blocking glial activation 
and the subsequent release of proinflammatory cytokines may minimize the development of 
opiate tolerance, providing more effective treatment for chronic pain, which is particularly 
advantageous for the treatment of neuropathic pain. 
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